Hints and tips:
Related Special Reports
...Additional reporting by Patrick McGee and Andrew Edgecliffe-Johnson...
...The research park’s own website says Alder is “a research laboratory focused on mycelium”....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...In clinical trials with sites in South Africa, both Johnson & Johnson and Novavax found their vaccines were less effective against the variant....
...Boris Johnson, the UK prime minister, said it was “good news” that the vaccine proved effective in the UK trial....
...“This news makes the results from Johnson & Johnson and Novavax even more important,” he added....
...The results are similar to those from other Covid-19 vaccines made by BioNTech/Pfizer, Moderna, and Johnson & Johnson, which have all shown varying degrees of efficacy against symptomatic Covid-19 in trials...
...Several other Covid-19 vaccines in development, including the Russian Sputnik-V and candidates from Johnson & Johnson of the US and CanSino of China, use adenoviruses....
...Mr Johnson argued that the home improvement trend had room to run....
...Idexx said in October that the animal health market had experienced a “V-shaped recovery”....
...There are civil suits against much larger companies including Johnson & Johnson and Teva, as well as distributors and pharmacies....
...These cells are now being tested in clinical trials; cells taken from a patient’s own bloodstream are matured into macrophages in the laboratory and then reinfused back into a patient with chronic liver...
...(New York Times) Deadly business Johnson & Johnson entered the death-penalty debate by obstructing Florida's plans to use the company's drugs for lethal injections....
...Investors need patience, he says, as regulators, patients and medical professionals gradually build confidence in new tech-driven approaches....
...The service, developed with surgeons at Imperial College London and top US institutions, has so far attracted more than 700,000 professional users....
...Pfizer, Johnson & Johnson and Celgene have also partnered with smaller companies in the CAR-T cell field....
...“A professional manager is supposed to be a manager that can manage whatever type of business, whether it is a healthcare, laboratory check-up, solar or whatever,” he says....
...Novartis and Johnson & Johnson have stepped up investment in a UK molecular diagnostics company developing a 30-minute test for sexually transmitted diseases....
...Pfizer, Johnson & Johnson and GlaxoSmithKline have all invested in cellular immunotherapy this year....
...Carson responds that scores on these laboratory tests of divergent thinking are correlated with substantial creative achievements such as publishing a novel, producing a professional stage show or creating...
...As soon as Gilead launched its new drugs, medical professionals warned that they risked busting the system....
...Andrew Jack is the FT’s head of aggregation and editor of FirstFT Photographs: V.A....
...Rivals such as GlaxoSmithKline and Johnson & Johnson began to embrace open innovation, liaising with networks of biotech start-ups....
...When Johnson & Johnson wanted to boost prescriptions of Natrecor, a heart medicine, it channelled more than $100,000 through a subsidiary company to a sympathetic nurse....
...(Johnson & Johnson has European rights to the drug.) Incivek has taken 80 per cent of the protease inhibitor market, leaving Merck’s Victrelis with the scraps....
International Edition